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Abstract
Background
Screening for type 2 diabetes (T2DM) and individuals at risk of diabetes has been advo-
cated, yet information on the response rate and diagnostic yield of different screening strat-
egies are lacking.
Methods
Studies (from 1998 to March/2015) were identified through Medline, Embase and the
Cochrane library and included if they used oral glucose tolerance test (OGTT) and WHO-
1998 diagnostic criteria for screening in a community setting. Studies were one-step strat-
egy if participants were invited directly for OGTT and two, three/four step if participants
were screened at one or more levels prior to invitation to OGTT. The response rate and
diagnostic yield were pooled using Bayesian random-effect meta-analyses.
Findings
47 studies (422754 participants); 29 one-step, 11 two-step and seven three/four-step were
identified. Pooled response rate (95% Credible Interval) for invitation to OGTT was 65.5%
(53.7, 75.6), 63.1% (44.0, 76.8), and 85.4% (76.4, 93.3) in one, two and three/four-step
studies respectively. T2DM yield was 6.6% (5.3, 7.8), 13.1% (4.3, 30.9) and 27.9% (8.6,
66.3) for one, two and three/four-step strategies respectively. The number needed to invite
to the OGTT to detect one case of T2DM was 15, 7.6 and 3.6 in one, two, and three/four-
step strategies. In two step strategies, there was no difference between the response or
yield rates whether the first step was blood test or risk-score. There was evidence of sub-
stantial heterogeneity in rates across study populations but this was not explained by the
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method of invitation, study location (rural versus urban) and developmental index of the
country in which the study was performed.
Conclusions
Irrespective of the invitation method, developmental status of the countries and or rural/
urban location, using a multi-step strategy increases the initial response rate to the invitation
to screening for diabetes and reduces the number needed to have the final diagnostic test
(OGTT in this study) for a definite diagnosis.
Introduction
Type 2 diabetes (T2DM) affects over 316 million people worldwide and is expected to rise to
552 million by 2030. [1] It is associated with high morbidity, mortality and healthcare costs. [2]
Screening for diabetes is feasible and identifies people with modifiable cardiovascular risk. [3]
Increasing global prevalence of people at high risk of diabetes [4] supports a case for early
detection and initiation of treatment of T2DM to prevent a high incidence of mortality and
morbidity. Screening for both diabetes and those at high risk followed by lifestyle interventions
has been suggested as being cost-effective [5,6] and may reduce long term complications. [6,7]
T2DM certainly meets many of the screening criteria. [8] There is evidence that screening for
diabetes has an overall benefit [6] with no harm to patients. [9] Many international organisa-
tions [2,6,7,10] have produced guidelines on screening for T2DM with information on screen-
ing tests and populations, yet none have made major recommendations regarding the
strategies to approach screening and the method of invitation.
There are a number of tests available for screening and diagnosing people with T2DM and
those at high risk of diabetes. One of the widely used methods is the oral glucose tolerance test
(OGTT).[4] However, other methods have also been suggested such as fasting plasma glucose,
[7] and non-invasive risk scores such as the FINDRISC. [11] Recently glycated haemoglobin
(HbA1c) has been suggested as a diagnostic tool by WHO [4] but it is still not universally stan-
dardized and many countries still recommend using OGTT. [4] NICE Guidance suggests the
use of various non-invasive screening tools followed by the use of diagnostic blood tests for
identifying those with diabetes or at high risk[6]. Cost, pragmatic problems in installation of a
new test, and higher prevalence of conditions such as haemoglobinopathies which undermine
the accuracy of HbA1c results are barriers to use this test in some developing countries.[12–15]
A number of studies have reported various combinations of methods of screening including
the use of risk scores which help in targeted screening followed by an OGTT. [16,17] These
risk score assessments are either patient led [11] or computer generated from general practice
records. [18,19]
However, there has been some uncertainty about the uptake of diabetes screening pro-
grammes in the real world setting. [20] Evidence on response to medical screening invitations
has varied depending on a number of factors including the level of social deprivation[21],
information on the severity of the disease, possible benefits of screening [22], the information
provided [23], and levels of anxiety. [24,25] Questions still remain about how screening should
be performed, in terms of producing the highest response rate and diagnostic yield.
Our objective was to perform a systematic review and meta-analysis of responses to differ-
ent methods of screening and their diagnostic yield using OGTT as an example of a definite
diagnostic test. We also sought to assess the effect of the countries developmental status,
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invitation type, locality and whether an invasive or non-invasive initial test was included on
these outcomes.
Methods
A systematic review was conducted to identify published articles on screening for T2DM. We
searched Medline, Embase and Cochrane online databases (1998- March/2015) using the head-
ings of ‘Diabetes’, ‘Prediabet’, “Glycemia’, ‘Impaired glucose tolerance’, ‘Impaired fasting’,
‘Screening’, etc. (Search strategies are included in the S1 Search Strategies). The reference lists
of all publications included at the full text review were checked manually. Only English lan-
guage papers were included.
Study selection
The initial search was performed by one reviewer and updated by another. A second reviewer
reviewed all the abstracts in the first search and 30% random selection of the updated searches.
All the selected full text articles were reviewed by two people. If any disagreement was not
solved through discussion a third reviewer was involved. Studies were included if the subjects
were free from T2DM at baseline, over the age of 18 and the screening and recruitment was
population based in a community setting and the WHO 1998/9 criteria [26] was used for diag-
nosis and the outcome of the study included diagnostic yield.
Quality Assessment and Data extraction. We used established guidelines on reporting
observational studies [27,28] to develop our quality assessment tool (Text and Table A in S1
Quality Assessment). Each reviewer scored the selected papers separately. Inter-reviewer
agreement achieved in 90%.
Authors (n = 15) were contacted via e-mail for missing data and followed up after 2–3 weeks
and unfortunately only five responded. Information on the study design, invitation method, risk
stratification, screening steps, age, geographical location, locality of settlement (urban versus
rural), were extracted. Prevalence of the diagnosis of T2DM, and those at high risk of diabetes
were extracted directly and the response rate to each test was calculated using data available in
the article. High risk population were defined as those with impaired glucose regulation: either
impaired fasting glucose [61 mmol/l (110 mg/dl) fasting glucose< 7 mmol/l (140mg/dl)] or
impaired glucose tolerance [78 mmol/l (140 mg/dl) 2 hours OGTT blood glucose< 111 mmol/
l (200 mg/dl)] or both.
Statistical methods
Outcome measures. We classified the screening strategies into one of three categories based
on the number of screening steps or stages employed by individual studies. Studies were classified
as a) one-step if participants were invited directly for OGTT without undergoing any pre-screen-
ing step, b) two-step if participants were invited for OGTT only after undergoing one inter-
mediate screening assessment to identify those at high risk of diabetes and c) three/four-step if
participants were invited for OGTT after undergoing pre-OGTT screening assessments at two or
three intermediate stages. The type of test employed at the intermediate steps included adminis-
tering non-invasive tools such as risk questionnaires or computer risk-scores or invasive tech-
niques (blood test) such as fasting or random glucose to identify at risk individuals.
For each strategy outlined above, we considered four outcomes i) initial response rate;
defined as the proportion of people accepted the invitation to a screening study divided by the
total number invited, ii) OGTT response rate defined as number responding to OGTT screen-
ing invitation divided by the total number invited to OGTT, iii) T2DM yield rate defined as the
number of newly diagnosed T2DM cases detected by OGTT divided by total number screened
Screening for Type 2 Diabetes
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using OGTT and iv) Diabetes and high risk yield rate defined as the combined number of
T2DM case and those at high risk of developing diabetes detected at the OGTT divided by total
number screened using OGTT.
The response rates were applied to a hypothetical population with 1000 adults to compare
the yield for each strategy (one step to multi-step) to demonstrate how the different approaches
compare if these strategies were implemented in a community setting.
Random effects model
The number of participants responding to a screening invitation or testing positive for diabetes
or at risk of diabetes was assumed to be drawn from a binomial distribution so that each study
independently estimated its own probability of response and a positive test. The logit of the
response and yield probabilities were assumed to be drawn from a normal distribution and
pooled across studies using Bayesian random effects meta-analysis.
The number needed to screen (NNS) to detect one T2DM case or the combined endpoint of
“diabetes and high risk” was calculated as the inverse of the respective mean yield rates.
The association between screening outcomes (i.e. response and yield rates) and pre-specified
study-level characteristics were explored and reported as response or yield rate ratios through uni-
variate meta-regression. To calculate these rate ratios, studies were classed according to: i) the
method of screening invitation or recruitment (postal/letter versus home visit/face-to-face invita-
tion), ii) the pre-OGTT step screening tests (invasive test versus non-invasive test), iii) the develop-
mental index of study’s country as defined by the United Nations Development programme http://
hdr.undp.org/en/data (developed versus developing country), and iv) the locality of the screening
(urban versus rural). The required rate ratios were defined simply as the pooled response or yield
rate in one category of a study-level characteristic (for example method of invitation) divided by
the corresponding pooled rate in a second category of study-level characteristic which has been
designated as the reference category. For example, in the meta-regression model investigating the
association between screening outcomes and method invitation, the response rate ratio was calcu-
lated as the pooled response rate in the postal invitation group divided the pooled response rate in
the non-postal (home visit or face-to-face) invitation group. The yield rate ratio is defined similarly
as the ratio of yield in the postal group to the yield in the non-postal group. All rate ratios were esti-
mated on the log-odds scale to ensure the assumptions underlying the random effects meta-analy-
sis model are applicable. Note that in the meta-regression models, studies were excluded if they
provided partial or insufficient information to enable the association between a particular study-
level characteristic and screening outcomes to be investigated. Heterogeneity of outcomes was
quantified using the between-study standard deviation in rates on the log-odds scale.
The impact of study quality on pooled OGTT response and yield rates was investigated by
restricting the analysis to studies with good quality ratings in a sensitivity analysis (Table A
and B in S1 Sensitivity Analysis).
All analyses were carried out using Markov Chain Monte Carlo simulations implemented in
the WinBUGS software version 143. [29] Minimally informative prior distributions were
placed on parameters so that the analysis results are almost entirely determined by the data
(model code is presented in the S1WinBUGS code: Random affects meta-analysis). 95%
credible intervals are presented throughout.
Results
Electronic searches and study selection
The flowchart of study identification and selection has been shown in Fig 1. The search identi-
fied 21398 articles, of which 395 were selected for full text review and 72 were included for data
Screening for Type 2 Diabetes
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extraction. Eleven studies [30–40] had to be excluded in this stage due to lack of data or incom-
plete reported data. Remaining 61 articles [41–100] were from 47 studies as some authors had
published their results in multiple articles and we reviewed all these related articles to increase
the accuracy of extracted data.
Characteristic of included studies
Tables 1 and 2 present summary statistics of the remaining 47 studies included in the analysis
grouped by the type of screening strategy. Twenty-three (49%) of the included studies were
conducted in Europe, 16 studies (34%) in Asia, 4 (85%) in Australia and New Zealand, 2
(4.3%) in the United States of American and another 2 (4.3%) in Africa. The age of participants
ranged from 18 to 94 years and about half of the studies were of mixed urban rural location.
Some studies were excluded from respective outcome analyses as they provided incomplete
information on response to OGTT, [41–47] initial response, [41,42,44–50] and yield for high
risk group. [41–50] Overall, 42 studies were included in the OGTT response rate, 38 in the ini-
tial response rate, and 35 in the combined “T2DM and at risk of diabetes” yield analysis.
Twenty-nine (617%) used OGTT alone (one-step screening approach (Table 1), 11 (234%)
used the two-steps screening strategy, three (66%) used a three-step strategy and four (88%)
Fig 1. PRISMA Flowchart of paper selection. † References –30–41. ‡ This is the number of journal articles included which equals to 47 studies as some
studies had reported their results in more than one paper.
doi:10.1371/journal.pone.0135702.g001
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used a four-step strategy. The intermediate strategies in these multi-step approaches included
risk score, fasting or random glucose and HbA1c.
Response rates
Estimates of pooled screening response rates are presented in Fig 2. The response rate for
OGTT as a proportion of those invited for OGTT was similar in studies using one-step and
two-step strategies at approximately 65% and higher in studies using a three/four-step strategy
at 854%. Among the studies using a multi-step screening strategy, the response rate to the ini-
tial screening invitation was 795% for the two-step strategy which is higher than the estimated
554% response the rate for studies using three/four-step strategy but there was considerable
overlap in the uncertainty (i.e. 95% credible intervals) around these estimates (Fig 1). Only the
studies using a three/four-step strategy had an intermediate screening step which had a pooled
response rate of 697%.
Positive outcome at initial and intermediate screening stages
The proportion of individuals screened positive (i.e. identified as being at risk of T2DM) at the
initial and intermediate stages of the multi-step strategies are summarised in Fig 3. These are
the individuals who needed to have the next step of the screening study. The positive outcome
rate was similar for two-step and three/four-step at 31.1% and 37.4% respectively at the initial
step and remained relatively the same for the intermediate screening step.
Yield rates
Pooled estimates of the yield for T2DM and the high risk (combined endpoint of T2DM and
those at high risk of diabetes) are presented in Fig 4. Yield for OGTT T2DM increased from
65% (53, 78) in the one-step to 131% (43, 309) in the two-step and 279% (86, 663) in the
three/four-step strategy. These yield rates correspond to number needed to screen with OGTT
to detect one case of diabetes of about 15, 7.6 and about 35 persons respectively.
Fig 2. Pooled response rates to diabetes screening invitation. Estimates are from Bayesian random effects meta-analysis. CrI = Credible intervals which
is similar to a confidence intervals generated using Frequentist statistics.
doi:10.1371/journal.pone.0135702.g002
Fig 3. Pooled positive outcome rates of diabetes screening using risk score, risk questionnaire and impaired glucose test. Estimates are from
Bayesian random effects meta-analysis. CrI = Credible intervals which is similar to confidence intervals generated using Frequentist statistics.
doi:10.1371/journal.pone.0135702.g003
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The overall T2DM yield (i.e. the total number of diabetes cases detected at all the steps as a
proportion of those screened at the initial step) in the multi-step strategy studies decreased
from the 65% in the one-step strategy reported above to 3.6% (26, 4.9) in the two-step strategy
and 32% (95% CrI 20, to 51) in the three/four-step strategy. These rates corresponds to an
increase in the number needed to screen at the initial step (OGTT if one-step strategy) from 15
in a one-step strategy to 28 and 31 in two-step and three/four-step strategies respectively.
Pooled estimates of the yield for the high risk (the combined endpoint of T2DM and those
at high risk of diabetes) were 258% (223, 295), 27.7% (133, 490) and 753% (435, 924) for
studies adopting one, two or three/four-step strategies respectively. The number needed to
screen to detect one additional person with diabetes or at risk of diabetes was decreased from 4
in a one-step strategy to 35 and 1 in two-step and three/four-step strategies.
We applied the mean response and yield rates from the meta-analysis to a hypothetical pop-
ulation of 1000 individuals in order to determine the diagnostic yield of the three screening
strategies (Fig 5). The number of individuals screened using OGTT decreased from 650 in a
one-step strategy to 156 and 45 in two-step and three/four-step screening strategies respec-
tively, and the number of T2DM cases identified decreased from 42 cases in one-step strategy
to 28 and 18 in the two-step and three/four-step strategies respectively.
Invasive versus Non-invasive tests
Seven of the 11 studies with a two-step strategy used an invasive test at the first screening step
(Table 2). There was no evidence that the OGTT response rate was higher in studies using an
invasive test than those using a non-invasive test [response rate ratio = 15, (03, 57)]. There
was a non-significant increase in the yield for T2DM and combined end point of the T2DM
and high risk population in studies using invasive test compared to non-invasive methods
[yield rate ratio were 64 (08, 439) and 23 (04, 133) respectively]. To compare the initial
response rates one study had to be excluded [19] as a computerised risk score was applied
instead of sending participants a risk questionnaire. Among the nine studies, there was no evi-
dence to suggest that the initial screening response differed between invasive and non-invasive
screening tests [response rate ratio = 49 (06, 437)].
The effect of invasive versus non-invasive tests on the outcomes of the three/four-step strat-
egies was not investigated as 6 of 7 studies employing this strategy used both invasive and non-
invasive tests at the intermediate screening steps.
Other covariate effect and subgroup analyses
Association between screening outcomes and three study-level characteristics: developed ver-
sus developing country, invitation method, and urban-rural level are presented in Table 3.
Fig 4. Pooled yield rates from diabetes screeningmeta-analysis. Estimates are from Bayesian random effects meta-analysis. CrI = Credible intervals
which is similar to a confidence intervals generated using Frequentist statistics. NNS* = Number needed to screen at OGTT step to detect one case of type 2
diabetes. NNS** = Number needed to screen at initial screening step (if a multi-step strategy is used) to detect to detect one case of type 2 diabetes.
doi:10.1371/journal.pone.0135702.g004
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There was no evidence that screening and yield rates were associated with a country’s develop-
mental index, the invitation method and the rural or urban location of the community.
Heterogeneity
The estimates of the between-study standard deviation (τ on the log-odds scale presented in S1
Sensitivity Analysis) indicate a high degree of heterogeneity in rates across studies using a
one-step, two-step and three/four-step strategies.
Sensitivity analysis
Restricting the analysis to studies assessed as good quality (S1Quality Assessment) did not
substantially alter pooled OGTT response and yield rates. The effect of study quality was not
investigated for the initial and intermediate screening outcomes because of insufficient data at
these steps.
In result reported above, we specified the following minimally informative prior distribu-
tions: i) Normal (0, 103) for pooled rate on the log-odds scale ii) Uniform (0,100) for the
between-study standard deviation. To investigate sensitivity of our results to the choice of prior
distributions, we conducted sensitivity analyses for the response and yield outcomes in which
Fig 5. Modelling the screening outcome in a community with 1000 adult population. *One Step
strategy = Direct invitation to OGTT (Studies in Table 1). **Two- Step strategy = One step screen before
OGTT (Studies in Table 2). ***Three/Four Step Studies = Two or three screening steps before OGTT
(Studies in Table 2).
doi:10.1371/journal.pone.0135702.g005
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we changed the prior distributions to iii) Normal (0, 106) for the pooled rate and ii) Inverse-
Gamma (0.001, 0.001) for the between-study variance. The pooled OGTT response rate was
65.2% (53.2% to 75.8%) for one-step strategy, 63.1% (48.2% to 76.9%) for a two-step strategy
and 85.1% (78.8% to 91.7) for a three/four-step strategy. These are very similar to main analysis
results (Fig 2) suggesting minimal impact of the prior distributions on the pooled response
rates. The sensitivity analyses were repeated for the yield outcomes and meta-regression analy-
ses (results not shown) with the same minimal effect on overall pooled rates.
Discussion
We have summarised and quantified the response and diagnostic yield rates of different screen-
ing strategies for T2DM and the high risk population. Our meta-analysis indicates that, for
those invited for OGTT screening, the number needed to screen to detect one T2DM case
decreases as the number of screening steps increases. We also showed that while the response
rates to OGTT invitation is the same for one and two steps screening strategies, the two-step
screening study has higher response rate to the initial screening invitation. In the two-step
strategies, there was no difference in the response and yield rates whether a blood test was used
as the initial screening step or a risk-score. We also showed that the method of invitation did
not impact the response rate; whether it was face to face or through post.
The use of risk classification and reclassification is based on the assumption that individuals
should be stratified into clinically relevant risk categories and for most risk scores the area
under the receiver operating characteristic curve generally range from 0.7 to 0.8, [101] which is
seen as an acceptable level of discrimination. Therefore the absolute number of people identi-
fied with diabetes or high risk decreases as the number of steps increases (see Fig 3). However,
a reduced number of OGTTs are performed to find a higher proportion of people with T2DM
or those at high risk. This is both the result of screening out the low risk population and also
the number of people who are not responding in each intermediary steps. Ultimately a prag-
matic point is that less people need to have OGTT screening when the screening steps increase.
Table 3. Association between screening outcomes and study level characteristics†:- i) developed/developing country‡ ii) rural/urban location and
iii) invitation method and screening response and yield rates from random effects meta-analysis of T2DM screening studies.
Screening strategy Study characteristic Screening response–response
rate ratio and 95% CrI
Screening yield–response ratio and 95% CrI
OGTT screening Initial Invitation OGTT-Diabetes Diabetes +at risk of diabetes
One step strategy Developing versus developed
country
2.27 (0.80, 6.55) 2.27 (0.80, 6.55) 1.46 (0.93, 2.28) 1.12 (0.74, 1.69)
Urban versus rural locality 0.94 (0.19, 4.96) 0.85 (0.07, 9.55) 1.81 (0.76, 4.38) 1.53 (0.74, 3.03)
Letter/Postal invitation versus
home visit/face to face invitation
0.80 (0.19, 3.41) 0.52 (0.14, 2.05) 0.90 (0.49, 1.69) 1.03 (0.60, 1.76)
Two step strategy Developing versus developed
country
2.12 (0.55, 8.39) 1.20 (0.14, 9.84) 4.96 (0.69, 32.65) 0.67 (0.08, 5.86)
Urban versus rural locality 0.17 (0.01, 4.34) NA 1.81 (0.76, 4.38) 1.21 (0.17, 11.51)
Letter/Postal invitation versus
home visit/face to face invitation
0.44 (0.03, 6.22) 0.09 (0.0, 11.4) 0.046 (0.03, 0.84) ND
ND = not enough data to carry out analysis. CrI = Credible intervals; Meta-regression analysis was not carried out for three and four step strategy due to
lack of data, OGTT = Oral Glucose Tolerance Test
†There was not enough data to perform this analysis for the three/four step studies.
‡Country classes as developed and developing according to United Nations Development Programme (UNDP) Human Development Index (HDI) for
2012. Their classiﬁcation are shown in Tables 1 and 2.
doi:10.1371/journal.pone.0135702.t003
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This has been suggested to be the most cost effective method [6, 102] and our study confirms
the two step methods has higher initial response rate to invitation, similar response rate to
OGTT invitation and higher yield rates.
Comparison with previous studies and recommendations
Screening for a condition is justified only if there is a net benefit in early detection and treat-
ment of the condition as compared to its natural clinical presentation. [103, 104] It has been
suggested that T2DM passes this test if a lifestyle intervention is implemented to prevent diabe-
tes in the high risk population. [5, 6] It is argued that universal screening would not be effective
or worthwhile, and that populations at risk should be identified and targeted. [105, 106] The
impact of screening at population and individual level, costs, type of test to use, and its effec-
tiveness have been highlighted as important factors in decision making [104, 105]. The evi-
dence for management of newly diagnosed diabetes and those at high risk of diabetes for early
intervention [107] and prevention [5, 108–111] is compelling. The ADDITION study demon-
strated that when compared to routine care, an intervention to promote target-driven, inten-
sive management of patients with type 2 diabetes detected by screening was associated with
modest but significant differences in prescribed treatment and levels of cardiovascular risk fac-
tors at five years. [112]
The question to answer is the methodology to approach to the screening task. Screening a
population using a non-invasive risk stratification tool followed by a definite blood test seems
the most cost-effective method of screening for T2DM and those at high risk [6, 102]. Stepwise
approach and adding an initial screening test (biochemical or risk score) before the “definitive
test” increases the yield from OGTT. Recently National Institute for Clinical Excellence also
recommended [6] screening for high risk population and offering blood test for those at high
risk of diabetes. Our results confirm this and may have an impact on the cost-effectiveness of
this recommendation.
Unfortunately due to lack of qualified studies we were unable to compare screening using
different tests such as random or fasting blood glucose, HbA1c, or the risk score as the initial
screening step. One study used HbA1c as a screening step [100]. It would also, be ideal if we
could report the difference between self-scoring and applied risk score and compare their
impact on the response rate to OGTT and overall yield of diabetes.
This is the first meta-analysis to determine response and yield rate when screening for
T2DM and people at high risk of diabetes. We used a wide terminology in initial searching for
the papers to increase the capture of the publications and reduce missing papers. There was a
variety of approaches in invitation and steps prior to the final definitive test (OGTT) and this
restricted the meta-analysis and subgroup analysis of the data, however we used robust statisti-
cal techniques. We only included the English language papers, but made no limitation on the
population size and analysed the data for different regions.
Some studies did not clearly report method of invitation, response rate or exact numbers of
participants partaking in certain screening steps. However missing data is always a problem in
evidence synthesis and we managed to recover some by contacting authors and or re-calculat-
ing the outcomes. Another limitation in any evidence synthesis is the fact that all studies are
not really and truly the same and combining their results may not be the real reflection of the
pooled outcomes. This is reflected in the high level of heterogeneity seen across all outcomes.
In our study; the number and order of the tests used before OGTT, impact of the self-score ver-
sus computer generated score, differences between different risk scores, possible impact of pop-
ulation dynamic and the psychosocial factors, wording of the invitation letter and its impact on
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the response to invitation are examples of some of the possible factors which we could not
truly account for their effects on our results.
We used OGTT as the definite test for diagnosis of diabetes. Although, the new guidelines
[4, 113] suggest the use of HbA1c for the diagnosis of diabetes, they do not exclude the use of
OGTT. Besides, some countries will continue to use OGTT as their screening tool. [12–15] A
detailed modelling is necessary to compare the cost-effectiveness of this approach with multi-
step screening.
Conclusion
We have been able to provide evidence for the overall response rate and yield of diabetes
screening in the background of a variety of factors such as geographical area, invitation meth-
ods and locality of the population (urban vs. rural) which influences decision making when
undertaking this task.
We can conclude that performing a multi-step approach in a population screening increases
the yield and decreases the number needed to screen by OGTT and in the two- step approach
it even increases the initial response rate to the invitation. In terms of absolute numbers, the
highest yield of diabetes, however, is obtained in the one step studies where an OGTT is offered
as a screening test to the population. The process of screening for T2DM or those at high risk
of diabetes needs careful re-evaluation by local policy makers in each country especially in view
of our findings.
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